Valion Bio (VBIO) Capital Expenditures (2022 - 2025)

Valion Bio has reported Capital Expenditures for 3 years, with the latest figure at $25000.0 in Q4 2025.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $25000.0 in Q4 2025; TTM through Dec 2025 was $35000.0, a 45.83% increase from a year earlier, with the FY2025 full-year figure at $38000.0, changed N/A from the prior year.
• Capital Expenditures was $25000.0 for Q4 2025 at Valion Bio, up from $10000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $94000.0 in Q1 2023, with the low at $5000.0 in Q3 2022.
• Average Capital Expenditures over 3 years is $27333.3, with a median of $17000.0 recorded in 2023.
• The largest YoY upside for Capital Expenditures was 1466.67% in 2023 against a maximum downside of 1466.67% in 2023.
• Over 3 years, Capital Expenditures stood at $5000.0 in 2022, then surged by 380.0% to $24000.0 in 2023, then increased by 4.17% to $25000.0 in 2025.
• The last three Capital Expenditures figures came in at $25000.0 (Q4 2025), $10000.0 (Q3 2025), and $24000.0 (Q2 2023), per Business Quant data.